NEW YORK (GenomeWeb) – MobiDiag, a Finnish molecular diagnostics company, is developing a new system to complement its existing catalog of quantitative PCR and microarray-based tests.

CEO Tuomas Tenkanen told BioArray News this week that the firm is at work on a new, high-throughput multiplexing platform and related diagnostic kits. While he declined to provide a launch date for the system, he described it as a "closed, cartridge-based instrument capable of detecting many targets in one assay."

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Researchers are refining a tool to predict a woman's risk of developing breast cancer, according to the Guardian.

According to Stat News, the partial government shutdown in the US could soon affect the ability of the Food and Drug Administration to review new drugs.

In PNAS this week: gypsy moth genome sequenced, phylogenomic analysis of Polyneopterans, and more.

CNN reports that people's genes tend to have a greater influence on their risk of developing disease than their environment, but it varies by phenotype.